...the logistics and accessibility of the specialized treatment centers, especially as payers become more sensitive to social determinants of health to drive health care disparities."
— Winston Wong, Pharm.D, president of W-Squared Group, spoke
with AIS’s Radar on Specialty Pharmacy about Kite Pharma, Inc.’s Tecartus, its
new approval in acute lymphoblastic leukemia, and how it will impact the market
basket.
No comments:
Post a Comment